CAJ | 학술논문

我国前列腺癌发病率呈逐年上升趋势，且大多数前列腺癌患者就诊时已处于中晚期，虽然内分泌治疗可使多数患者的病情在一定程度上能得到控制和改善，但其中绝大多数患者发展为去势抵抗性前列腺癌（castration resistant prostate cancer， CRPC）。此类患者预后极差，治疗颇为棘手，因此迫切需要新的治疗策略。精准医学能够根据每位患者的基因特征指导临床个体化治疗。本文就CRPC发病机制和靶向治疗药物的研发、指导个体化治疗的临床试验进行综述，以总结和探讨CRPC精准医学研究的进展。
아국전렬선암발병솔정축년상승추세，차대다수전렬선암환자취진시이처우중만기，수연내분비치료가사다수환자적병정재일정정도상능득도공제화개선，단기중절대다수환자발전위거세저항성전렬선암（castration resistant prostate cancer， CRPC）。차류환자예후겁차，치료파위극수，인차박절수요신적치료책략。정준의학능구근거매위환자적기인특정지도림상개체화치료。본문취CRPC발병궤제화파향치료약물적연발、지도개체화치료적림상시험진행종술，이총결화탐토CRPC정준의학연구적진전。
Most prostate cancer (PCa) patients in China are diagnosed at an advanced stage. Many PCa patients are initially sensi-tive to hormonal therapy and experience temporary tumor regression, but nearly all of the patients will finally reach a state of castration-resistant prostate cancer (CRPC). CRPC is difficult to cure and thus has poor prognosis. Identification of new therapies to treat CRPC remains an urgent need. Precision medicine individualizes CRPC treatments by tailoring them to the genomic characteristics of CRPC. In this review, we summarize the recent progress of pathogenesis, molecular targeted therapy, and clinical trials of CRPC as well as dis-cuss precision medicine for CRPC.